Health · Pharma & Biotech · 2 hrs ago
Ianalumab Trials Leave Its Path to Sjögren’s Approval Uncertain
Two randomized trials of ianalumab for Sjögren’s disease have been published.
Ianalumab is an anti-B cell biologic being studied as a treatment for the disease.
The trial findings have left its path to regulatory approval uncertain.
The published results may not be enough to support approval by regulators.
That uncertainty matters for the drug’s prospects as a treatment option.
The available information does not specify what regulators will decide or what steps come next.
Findings from two randomized trials of ianalumab for Sjögren’s disease have been published.
The results leave it unclear whether the trials are sufficient to support regulatory approval.
Ianalumab is an anti-B-cell biologic.
- Who
- Researchers studying ianalumab in people with Sjögren’s disease.
- What
- Findings from two randomized trials were published, but their sufficiency to support regulatory approvals is unclear.
- When
- The article was published on October 21, 2026.
- Where
- Not stated.
- Why
- The published trial findings have left uncertainty about whether the evidence is sufficient to support regulatory approvals.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Trials
- Two randomized trials
- Drug
- Ianalumab
- Drug type
- Anti-B-cell biologic
- Disease
- Sjögren’s disease
- Publication date
- October 21, 2026